Winrevair Shows Promise in Advancing PAH Treatment | ACC 2025
March 31st 2025Marc Humbert, M.D., Ph.D., professor of respiratory medicine at Université Paris-Saclay and Inserm, believes that recent clinical trials have reinforced the potential of Winrevair (sotatercept) as a breakthrough in pulmonary arterial hypertension (PAH) treatment.
Read More
GLP-1s Are an 'Adjunct to Lifestyle Management' | ACC 2025
March 30th 2025In this second part of his interview with Managed Healthcare Executive, John B. Buse, M.D., Ph.D., a professor at the University of North Carolina (UNC) School of Medicine and director of the UNC's Diabetes Care Center, discusses lifestyle management and GLP-1s.
Read More
The Fight to Make GLP-1s Cost-Effective as Demand Increases | ACC 2025
March 30th 2025John B. Buse, M.D., Ph.D., a professor at the University of North Carolina (UNC) School of Medicine and director of the UNC's Diabetes Care Center, pointed to research that has shown a price of $150 per month would make the GLP-1s cost-effective as a prevention measure.
Read More